These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 31131629)

  • 1. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
    Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
    Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
    Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
    J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
    N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
    J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
    Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
    Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial.
    Toth PP; Jones SR; Slee A; Fleg J; Marcovina SM; Lacy M; McBride R; Boden WE
    J Clin Lipidol; 2018; 12(3):741-747.e11. PubMed ID: 29627296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE
    J Am Coll Cardiol; 2013 Oct; 62(17):1580-4. PubMed ID: 23916935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.
    Probstfield JL; Boden WE; Anderson T; Branch K; Kashyap M; Fleg JL; Desvigne-Nickens P; McBride R; McGovern M;
    J Clin Lipidol; 2018; 12(6):1413-1419. PubMed ID: 30131256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
    Teo KK; Goldstein LB; Chaitman BR; Grant S; Weintraub WS; Anderson DC; Sila CA; Cruz-Flores S; Padley RJ; Kostuk WJ; Boden WE;
    Stroke; 2013 Oct; 44(10):2688-93. PubMed ID: 23881958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
    Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.